Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit HR may repres...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Young Eun, Battelli, Chiara, Watson, Jacqueline, Liu, Joyce, Curtis, Jennifer, Morse, Alexander N., Matulonis, Ursula A., Chowdhury, Dipanjan, Konstantinopoulos, Panagiotis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058036/
https://www.ncbi.nlm.nih.gov/pubmed/24798692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058036/
https://www.ncbi.nlm.nih.gov/pubmed/24798692

Ejemplares similares